The main aim of this proposal is to analyze gene expression patterns in cancer of the prostate and to establish correlations with distinct groups of cancer behavior. These cancer subgroups are currently covered under histopathologic diagnoses that do not allow prediction of behavior from morphologic criteria. The studies will allow us to establish a molecular reclassification of prostate cancer based on coordinated expression of groups of specific genes. Complete prostatectomy specimens available in our Western Pennsylvania Prostate Tissue Bank (run by our department of Pathology) will be processed by microdissection and used to extract RNA. This will in turn be processed for analysis through the Affymetrix gene chip set, based on existing active strong and long term commitment of collaboration with the Molecular Oncology team of Hoffman LaRoche, Inc., at Nutley, New Jersey and our department of Pathology at the University of Pittsburgh. Our tissue bank contains complete and well stratified information that will be used by the bioinformatics teams of HLR and Pitt to provide correlation between coordinated expression of specific gene sets and distinct tumor behavior. We will be processing prostate cancer samples from the following groups: 1. Normal prostate. 2. Prostatic cancer without capsular invasion. 3. Prostatic cancer with capsular invasion that did not progress to systemic disease. 3. Prostatic cancer with capsular invasion that did progress to widespread systemic disease. 4. Metastatic foci. The data from the gene expression analysis will be processed by both the Pitt and the HLR bioinformatics team to provide cohesive and complete correlation from gene expression to clinical behavior, in order to establish new diagnostic groups of prostate cancer based on molecular sub- classification. Subsequent studies will also use the Differential Subtraction Chain technique and Fluorescence In Site Hybridization (FISH) to conduct complete genomic screening of the new sub-classification groups in order to detect genomic abnormalities that correlate with the gene expression patterns in the groups established from the above studies. While altered expression patterns are undoubtedly to become the basis for future tumor diagnostic methodology, repeated paradigms with all types of cancer suggest that the basis for altered gene expression patterns in tumors is the accumulation of genomic alterations linked to tumor progression. The integrated approach of this proposal will allow not only molecular sub-classification of prostate cancer but also establishment of easy to perform diagnostic tools (selective gene expression analysis by Real Time PCR Matrix, detection of genomic abnormality markers, etc.) that can be easily applied as predictors for tumor behavior. Preliminary results already provide strong evidence of correlation between invasive behavior and altered expression of specific genes. These include altered expression of membrane bound proteases and matrix bound growth factors, as well as increase in groups of G-protein linked receptors and the ligands, and decrease in enzymes responsible for their degradation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA088110-05
Application #
6701753
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (M1))
Program Officer
Jacobson, James W
Project Start
2000-08-29
Project End
2006-01-31
Budget Start
2004-02-01
Budget End
2006-01-31
Support Year
5
Fiscal Year
2004
Total Cost
$677,203
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Ren, Baoguo; Yu, Yan P; Tseng, George C et al. (2007) Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 99:868-80
Chandran, Uma R; Ma, Changqing; Dhir, Rajiv et al. (2007) Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7:64
Yu, Guoying; Tseng, George C; Yu, Yan Ping et al. (2006) CSR1 suppresses tumor growth and metastasis of prostate cancer. Am J Pathol 168:597-607
Ren, B; Yu, G; Tseng, G C et al. (2006) MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 25:1090-8
Yu, Yan Ping; Tseng, George C; Luo, Jian-Hua (2006) Inactivation of myopodin expression associated with prostate cancer relapse. Urology 68:578-82
Yu, Yan Ping; Luo, Jian-Hua (2006) Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res 66:7414-9
Gologan, Adrian; Bastacky, Sheldon; McHale, Teresa et al. (2005) Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues. Am J Surg Pathol 29:1435-41
Chandran, Uma R; Dhir, Rajiv; Ma, Changqing et al. (2005) Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5:45
Yu, Yan Ping; Paranjpe, Shirish; Nelson, Joel et al. (2005) High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 26:471-9
Yu, Yan Ping; Landsittel, Douglas; Jing, Ling et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22:2790-9

Showing the most recent 10 out of 16 publications